56,206 Shares in Repligen Corporation $RGEN Acquired by Woodline Partners LP

Key Points

• Woodline Partners LP has acquired 56,206 shares of Repligen Corporation valued at approximately $7.15 million, representing about 0.10% ownership of the company.
• Various hedge funds have recently increased their stakes in Repligen, with institutional investors now owning 97.64% of the stock.
• Repligen's shares have received favorable ratings from several analysts, with a consensus rating of "Moderate Buy" and an average price target of $166.67.

Woodline Partners LP bought a new position in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund bought 56,206 shares of the biotechnology company's stock, valued at approximately $7,152,000. Woodline Partners LP owned approximately 0.10% of Repligen at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. KBC Group NV grew its stake in Repligen by 14.9% during the 1st quarter. KBC Group NV now owns 2,544 shares of the biotechnology company's stock worth $324,000 after purchasing an additional 329 shares in the last quarter. Harvest Fund Management Co. Ltd acquired a new position in Repligen during the 1st quarter worth $132,000. XTX Topco Ltd grew its stake in Repligen by 34.2% during the 1st quarter. XTX Topco Ltd now owns 12,935 shares of the biotechnology company's stock worth $1,646,000 after purchasing an additional 3,295 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Repligen by 40.1% during the 1st quarter. GAMMA Investing LLC now owns 958 shares of the biotechnology company's stock worth $122,000 after buying an additional 274 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd lifted its holdings in Repligen by 233.6% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 9,208 shares of the biotechnology company's stock worth $1,172,000 after buying an additional 6,448 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

RGEN has been the subject of a number of recent analyst reports. Jefferies Financial Group decreased their price target on Repligen from $145.00 to $135.00 and set a "hold" rating for the company in a report on Friday, September 12th. Wells Fargo & Company decreased their price target on Repligen from $180.00 to $175.00 and set an "overweight" rating for the company in a report on Wednesday, July 30th. Evercore ISI decreased their price target on Repligen from $140.00 to $130.00 and set an "in-line" rating for the company in a report on Tuesday, July 8th. Stephens raised Repligen to an "overweight" rating and set a $160.00 price target for the company in a report on Tuesday, July 22nd. Finally, Royal Bank Of Canada reaffirmed an "outperform" rating and set a $205.00 price target on shares of Repligen in a report on Tuesday, September 2nd. Eight research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $166.67.

Insider Activity

In other Repligen news, Director Martin D. Madaus bought 1,800 shares of the business's stock in a transaction dated Friday, August 8th. The stock was acquired at an average cost of $112.13 per share, with a total value of $201,834.00. Following the purchase, the director owned 1,800 shares in the company, valued at approximately $201,834. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 1.20% of the company's stock.

Repligen Stock Performance

Shares of Repligen stock traded up $4.26 on Thursday, hitting $123.65. The stock had a trading volume of 350,797 shares, compared to its average volume of 776,326. Repligen Corporation has a 52-week low of $102.96 and a 52-week high of $182.52. The company has a current ratio of 8.59, a quick ratio of 7.32 and a debt-to-equity ratio of 0.26. The stock has a market cap of $6.96 billion, a price-to-earnings ratio of -494.60, a P/E/G ratio of 2.21 and a beta of 1.07. The company's 50 day moving average price is $120.13 and its 200 day moving average price is $127.15.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.40 by ($0.03). The company had revenue of $182.37 million during the quarter, compared to analyst estimates of $174.62 million. Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The business's revenue was up 14.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.40 EPS. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. On average, research analysts anticipate that Repligen Corporation will post 1.72 EPS for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.